Key Drivers
- High gross margin
- Strong free cashflow
- Elevated leverage/valuation
AIAI Summary
Masimo has transitioned into a deal‑driven turnaround where the realized value is contingent on Danaher's $180 bid and favorable legal outcomes—operational improvements (positive quarterly FCF and strong gross margins) offer a path to justify the premium, but consumables reacceleration, contract convertibility, tariff headwinds, and litigation risk are the decisive factors that will determine whether the market re-rates the stock or discounts it sharply.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Strong free cashflow
- •Elevated leverage/valuation
MASI combines strong gross margins and cash generation with a positive recent quarter but faces full-year operating losses, high valuation and meaningful noncurrent liabilities that require sustained opex control to secure profitability.
Price Behavior
Key Price Behavior Insights:
- •Tight support
- •Nearby resistance
- •Low volatility
MASI has shown mild upside over the last month (up ~1–2% from mid‑$175s to $178.24) trading in a low‑volatility range with key signals being a sustained break above ~$178 (bullish) or a drop below ~$175 (bearish).
Large, abrupt price swings 2026‑02‑13 to 2026‑02‑19 suggest a corporate action or data error that should be verified
Sentiment & News
Key News Insights:
- •Institutional accumulation
- •Momentum/value debate
- •Regulatory investigations
Early‑2026 headlines show rising institutional interest and stylistic momentum in Masimo (MASI) alongside repeated Halper Sadeh shareholder‑rights investigations alleging potential differential insider benefits.
Growing buy‑side support could boost MASI's multiples in the near term, but ongoing probes create legal overhang and higher volatility until resolved
Similar Companies in Healthcare
Other companies in the same sector with AI ratings